Abbott Laboratories News

BRITISH Energy failed to power ahead yesterday despite reports that an imminent bid for the East Kilbride-based group would be priced at about 775p-a-share. Shares in BE edged 2p lower to 726.5p after surging ...

Cocktails of HIV drugs help patients live an average of 13 years longer -- if they are lucky enough to get them, researchers reported on Thursday.

Abbott Laboratories said it received a subpoena last month from the U.S. Justice Department in connection with the sales and marketing of its biliary stents.

Cocktails of HIV drugs help patients live an average of 13 years longer -- if they are lucky enough to get them, researchers reported on Thursday.

Large, mature growth company. Business = Diversified healthcare, including drugs, medical devices, and nutritional products.

One of Southwest County's biggest employers soon will be laying off hundreds of its workers.

'Fidelity Select Pharmaceuticals, with a 4.2% gain, ranked third among Select funds and was among the top 20% of health care funds for the month, shooting up 13 places on the Sector Momentum Table,' said Don ...

Both companies wanted to give researchers time to release clinical trial data on their cholesterol-lowering drug Vytorin.

Three rheumatoid arthritis drugs should not be given to patients on Britain's state-run health service when similar drugs have already failed, the country's healthcare cost-effectiveness body said on Monday.

Abbott Laboratories results - MarketWatch Intraday data provided by Interactive Data Real Time Services , a division of Interactive Data Corp.

Investors are always being told to diversify. Losses in one section of the portfolio can be overcome in other areas.

Guidance Analysts are looking for a profit of 79c on revenue of $7.23B. The consensus range is 76c to 79c for EPS, and revenue of $7.15B to $7.38B, according to First Call.

Abbott Laboratories July 16, 2008, 09:00 AM ET Executives John B. Thomas - VP, IR Thomas C. Freyman - EVP, Finance and CFO Analysts Michael Weinstein - J.P. Morgan Lawrence Keusch - Goldman Sachs Bruce Nudell - ...

Abbott Labs posted better than expected earnings and sales growth and raised its guidance this morning, reflected in the 1-year stock chart posted on my blog which shows that the company has outperformed the ...

Abbott Laboratories Inc. beat Wall Street expectations Wednesday with a 34 percent jump in the second-quarter profit, driven by robust sales of its blockbuster drug Humira and increased business overseas.

Abbott Laboratories Inc. says its second-quarter profit rose 34 percent, driven by robust sales of its drugs and medical devices.

We read with interest the report by Giulieri et al1 on professional exposures to patients with acute primary human immunodeficiency virus infection with high viral load and a positive P24 antigen test result ...

Abbott Laboratories, the fourth-biggest U.S. drugmaker, must face a trial on claims it deceived workers who joined its Hospira Inc.

Abbott Laboratories Inc. said July 2 that a stent designed, developed and manufactured by its Silicon Valley unit has been approved by the U.S. Food and Drug Administration.

New Jersey drugmakers have notified the state they plan to cut more than 1,100 jobs.